Expanding the Classification of Leukemia by the World Health Organization over Time

Maedeh A, Bita D, Shiva E and Gholamhossein T*
Shiraz University of Medical Sciences, Iran

*Corresponding author: Gholamhossein Tamaddon, Shiraz University of Medical Sciences, Zand St, Shiraz, Iran, Tel: +989151417043; Email: tamaddon.g@gmail.com

Abstract

The classification has always been the basis for many treatments of the disease. The French-American-British has performed leukemia classification base on morphological finding, but the World Health Organization apply gene or chromosomal mutations in its classification. This approach has revolutionized the diagnosis, choose strategy of treatment and follow-up ever since. Although WHO has classified leukemia on the basis of FAB; but genetic mutations has made the wider and more specific outcome. Obviously, identifying these damages provide an extensive filed for researchers and physicians to effective assistance for patients. Therefore, the purpose of this review is comparing revisions of WHO classification in the years 2008 and 2016, because these categories are highlighted unknown cases that give researchers incentives to further study.

Keywords: World Health Organization; leukemia Classification; Chromosomal mutations

Abbreviations: FAB: French-American-British; WHO: World Health Organization; TKI: Tyrosine Kinase Inhibitor; AP: Accelerated-Phase; CNL: Chronic Neutrophilic Leukemia; CSF3R: Colony-Stimulating Factor 3 Receptor; PV: Polycythemia Vera; RCM: Red Cell Mass; EEC: Endogenous Erythroid Colony; ET: Essential Thrombocytemia; PMF: Primary Myelofibrosis; MPN/MDS: Myeloproliferative/Myelodysplastic Neoplasm; CEL-NOS: Chronic Eosinophilic Leukemia, Not Otherwise Specified; CMML: Chronic Myelomonocytic Leukemia; JMML: Juvenile Myelomonocytic Leukemia.

Introduction

The purpose of each classification of hematological neoplasms is to provide reliable criteria for diagnosis and also appropriate classification of them. These classifications has changed over time. Surprisingly, given the advancement of molecular study and the identification of newer and more specific factors, changes to these categories occur simultaneously with changes in advances science. In 1982, French-American-British (FAB) group presented a classification by using morphological and cytochemical characteristic of blast cells. By developing diagnostic methods and identifying molecular aspects of leukemia, the World Health Organization (WHO) expanded this classification by maintaining the FAB classification. The basic principle of the WHO is that information about, genetic, immunophenotypic, biologic, and clinical features along with morphology should be considered, in order to accurately diagnose and determine the protocol of treatment based on it. Also in WHO classification the number of blasts necessary for the diagnosis is more than 20% in bone marrow when compared 30% in FAB classification. Since 2001, when
the WHO presented this report, these categories have been updated and updated. The latest changes are for 2016. Based on these concepts, the progression of the diagnostic criteria, it is anticipated that prognosis, quality of life and patient survival will improve in the future. This review attempts to compare these changes over the years. Also focus on known mutation during this time and emphasis on the search for unknown mutations.

**Myeloproliferative Neoplasm (MPN)**

Classification of MPNs have not changed remarkably since the 2008 edition, but discoveries of new mutations and improved understanding of the morphologic characteristics of some entities have impacted the diagnostic criteria for the disease entities. Table 1 lists diseases encompassed in the MPNs and compares the 2016 revision with that of the 2008 classification.

**Table 1:** The 2008 and 2016 WHO Classification of MPNs.

<table>
<thead>
<tr>
<th>2008</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic myelogenous leukemia(CML), BCR-ABL1 +</td>
<td>Chronic myeloid leukemia(CML), BCR-ABL1+</td>
</tr>
<tr>
<td>Chronic Neutrophilic Leukemia (CNL)</td>
<td>Chronic Neutrophilic Leukemia (CNL)</td>
</tr>
<tr>
<td>Polycythemia Vera (PV)</td>
<td>Polycythemia Vera (PV)</td>
</tr>
<tr>
<td>Primary Myelofibrosis (PMF)</td>
<td>Primary Myelofibrosis (PMF)</td>
</tr>
<tr>
<td>PMF, prefibrotic/early stage</td>
<td>PMF, overt fibrotic stage</td>
</tr>
<tr>
<td>Essential Thrombocythemia (ET)</td>
<td>Essential Thrombocythemia (ET)</td>
</tr>
<tr>
<td>Chronic Eosinophilic Leukemia, NOS</td>
<td>Chronic Eosinophilic Leukemia not otherwise specified, (CEL-NOS)</td>
</tr>
<tr>
<td>Mastocytosis Myeloproliferative Neoplasm</td>
<td>Mastocytosis unclassifiable (MPN-U)</td>
</tr>
<tr>
<td>unclassifiable</td>
<td></td>
</tr>
</tbody>
</table>

**Chronic Myeloid Leukemia (CML)**

Based on the 2016 update of WHO classification the "myelogenous" is replaced with "myeloid" in CML. So the name of chronic myelogenous leukemia is changed to myeloid leukemia.

By identifying the BCR-ABL1 fusion gene in this group of patients, tyrosine kinase inhibitor is considered as a first-line treatment. In the new classification criteria for diagnosis, accelerated-phase (AP) was revised. So “response to tyrosine kinase inhibitor (TKI)” criteria have been added to the definition of AP disease. These include: a) Hematologic resistance to first TKI b) Hematologic, cytogenetic, or molecular indications of resistance to two sequential TKIs c) Occurrence of two or more mutations in BCR-ABL1 during TKI therapy [1].

Table 2 shows Response criteria of TKI therapy [2].

**Table 2:** Response criteria of TKI therapy.

<table>
<thead>
<tr>
<th>Time on TKI therapy</th>
<th>ELN /NCCN recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Optimal</td>
</tr>
<tr>
<td>baseline</td>
<td>NA</td>
</tr>
<tr>
<td>3 months</td>
<td>BCR-ABL1 ≤ 10% and/or Ph+ ≤ 35%</td>
</tr>
<tr>
<td>6 months</td>
<td>BCR-ABL1 ≤ 1% and/or Ph+ 0</td>
</tr>
<tr>
<td>12 months</td>
<td>BCR-ABL1 ≤ 0.1%</td>
</tr>
<tr>
<td>18 months</td>
<td>Then, and at any time BCR-ABL1 ≤0.1%</td>
</tr>
</tbody>
</table>

ELN: European Leukemia Net; NCCN: National Comprehensive Cancer Network; NA: not available; CCA: Clonal Chromosome Abnormalities; CHR: Complete Hematological Response defined as WBC < 10 × 10⁹/L, Basophils <5%, No myelocytes, promyelocytes, myeloblasts in the differential, Platelet count <450 ×10⁹/L, Spleen non-palpable; CCgR: Complete Cytogenetic Response defined as no Ph+ metaphases on chromosome banding analysis (at least 20 bone marrow cell metaphases) or <1% BCR-ABL1 positive nuclei of at least 200 nuclei on fluorescence in situ hybridization. MMR: Major Molecular Response defined as BCR-ABL1 expression of ≤0.1% on the international scale.
Chronic Neutrophilic Leukemia (CNL)

CNL is a clonal disorder in which neutrophils proliferate uncontrollably. In the new category in 2016, diagnostic cases of CNL are divided into the major and minor criteria. Also, in the new classification, presence of colony-stimulating factor 3 receptor (CSF3R) T618I or other membrane-proximal CSF3R mutations have been added to CNL criteria diagnosis [3,4]. CSF3R is the primary growth factor of neutrophil production. The CSF3R mutation has two categories: truncation mutations and membrane proximal mutations. CSF3R membrane proximal mutations may be sensitive to JAK kinase inhibitors such as ruxolitinib. While truncation mutations displayed sensitivity to inhibition with SRC kinase inhibitor Dasatinib [4,5].

Polycythemia Vera (PV)

Polycythemia Vera is one of the Philadelphia chromosome-negative myeloproliferative neoplasms which is characterized by proliferation of erythroid, granulocytic and megakaryocytic elements in the bone marrow that are called pannymelosis. According to the 2016 WHO classification, due to the importance of red cell mass (RCM) parameter and the effect of hematocrit on it, the Hct parameter was considered as a suitable measure for the detection of PV. The optimal cutoff of hematocrit was considered 49% in men and 48% in women, and the hemoglobin level of 16.5g / dl and 16g/ dl in men and women respectively has been determined for distinguishing masked/prodromal PV patients from JAK2 mutated ET. According to the new revision the level of EPO as the only minor criterion is considered. Whereas a low serum EPO is specific for PV and therefore clinically useful, approximately 20% of PV patients present with normal and a few even with high EPO values [6-8]. Based on the 2016 WHO classification, bone marrow morphology has been considered as a major criterion for detecting PV. A slight increase in reticulin levels has been observed in patients with bone marrow biopsy. Increased reticulin fibrosis is associated with the progression of the disease to Post PV myelofibrosis [8,9]. The endogenous erythroid colony (EEC) in the 2016 classification has been eliminated due to time and cost [9].

Essential Thrombocythemia (ET)

ET is a clonal stem cell disease and one of the Philadelphia chromosome-negative myeloproliferative neoplasms which is associated with persistent thrombocytosis. According to the classification of 2016, MPL (the thrombopoietin receptor) and CALR (Calreticulin) mutations have been added to ET diagnostic criterion. 10-16% of ET cases are triple negative. Compared to JAK2-mutated cases, the association of CALR mutation with younger age, male gender, lower leukocyte count, lower Hb level and higher platelet counts is seen, and the thrombotic risk is also lower in them. In the 2016 classification increased levels of reticulin fibers (grade 1) have been observed in major criteria [10].

Primary Myelofibrosis (PMF)

PMF is a Philadelphia-negative myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation with a predominant proliferation of Megakaryocytes and granulocytes in the bone marrow. Bone marrow is filled with fibrous tissue, although in some cases the bone marrow is hyperplastic and very little fibrosis is seen [11,12]. PMF is categorized into Pre-PMF and Overt-PMF (based on the 2016 WHO classification) which may have a major effect on accurate diagnosis and outcome and prognosis. This distinction is important because prePMF can be confused with ET because of similar symptoms. Detection based on poor prognosis, increased mortality and leukemic transformation rate for prePMF compared with ET. In the 2016 classification CALR and MPL mutation were added to major criteria of PMF [1,12]. Table 3 compares 2008 and 2016 WHO criteria for PMF.

<table>
<thead>
<tr>
<th>Major Criteria</th>
<th>2008</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megakaryocyte proliferation and atypia accompanied by either reticulin and/or collagen fibrosis; or in absence of reticulin fibrosis, megakaryocyte changes must be accompanied by increased marrow cellularity, granulocytic proliferation, and often decreased erythropoiesis (i.e., pre-fibrotic)</td>
<td>Megakaryocytic proliferation and atypia, without reticulin fibrosis grade 1, accompanied by increased age-adjusted bone marrow cellularity, granulocytic proliferation and often decreased erythropoiesis</td>
<td>Megakaryocyte proliferation and atypia accompanied by either reticulin and/or collagen fibrosis (grade 2 or 3)</td>
</tr>
</tbody>
</table>
PMF)

<table>
<thead>
<tr>
<th>Not meeting WHO criteria for CML, PV, MDS, or other myeloid neoplasm</th>
<th>Not meeting WHO criteria for BCR-ABL1+ CML, PV, ET, MDS or other myeloid neoplasm</th>
<th>Not meeting WHO criteria for BCR-ABL1+ CML, PV, ET, MDS or other myeloid Neoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demonstration of JAK2V617F or other clonal marker; in absence of clonal markers, no evidence of secondary bone marrow fibrosis</td>
<td>Presence of JAK2, CALR or MPL mutation or in the absence of these mutations, presence of another clonal marker or absence of minor reactive bone marrow reticulin fibrosis</td>
<td>Presence of JAK2, CALR or MPL mutation or in the absence of these mutations, presence of another clonal marker or absence of minor reactive bone marrow reticulin fibrosis</td>
</tr>
</tbody>
</table>

Table 3: Comparison of 2008 and 2016 criteria of PMF.

The common mutation types are type 1 mutation (p, L367fs*47) which results from 52-bp deletion, and type 2 mutation (p.K385fs*47) which results from a 5-bp TTGTC insertion within exon 9 of the gene. Both types of mutations cause a single base pair frame shift which results in the formation of a new mutant C-Terminal peptide composed of minimal 36 amino acids which replace the 27 amino acids that are lost from the normal sequence. The mutated C-domain contains positively charged amino acids because of eliminating the negative charge; so the Ca²⁺ binding function is impaired. Type 1 mutations remove all of the negatively charged amino acids but in type 2 mutations almost up to half of the positively charged amino acids are sustained. Also, in both types of mutation the KDEL motif is lost so mutant CALR have an abnormal Ca²⁺ binding and cell growth [13,14] (Figures 1 & 2).

Figure 1: Shows the structure of Calreticulin (CALR) gene in chromosome 19. Three domains of CALR are N-Domain, P-Domain (chaperon domain) and C-Domain which is rich in acidic amino acids (binding site for Ca²⁺). Normal C-domain of CALR gene is comprised of acidic amino acids such as lysine(K), aspartate(D), glutamate(E), and leucine(L) that is KDEL signal.

Figure 2: Shows the structure of Calreticulin (CALR) gene in chromosome 19. Three domains of CALR are N-Domain, P-Domain (chaperon domain) and C-Domain which is rich in acidic amino acids (binding site for Ca²⁺). Normal C-domain of CALR gene is comprised of acidic amino acids such as lysine(K), aspartate(D), glutamate(E), and leucine(L) that is KDEL signal.
1. Mutant CALR has a positive charge because of frame shift mutations in exon 9
2. Mutant CALR bind to the TR that cause TPO-independent activation
3. JAK2 binds to TR and increases this receptor’s activity
4. STAT5 tyrosine-phosphorylated by JAK2
5. Homodimers of STAT translocate to the cell nucleus
6. Homodimers of STAT induce transcription of target gene

TR: Thrombopoietin Receptor; CALRmut: Calreticulin mutant gene; JAK: Janus kinase; STAT: Signal Transducer and Activator of Transcription.

**Figure 2:** Muted CALR bind to Thrombopoietin Receptor (TR) and increase STAT5 signal activity by JAK2.

**Mastocytosis**

Mastocytosis is a term used for clonal accumulation of mast cells (MCs) in different organs. Most patients with mastocytosis have characteristic skin lesions. Increased levels of mast cell tryptase are considered as an indicator of disease. The WHO update of 2016 recommends use of the following new synonym: AHN (associated hematologic neoplasm) and SM-AHNMD (SM with clonal hematologic non-mast cell lineage disease) and may be used interchangeably. So AHN and SM-AHNMD, can be used interchangeably [15,16]. In ASM patients, the percentage of Mast cells in bone marrow is important. For this reason, in the new revision of WHO, the disease is divided into two categories: transformed ASM (ASM-t) and untransformed variant. In ASM-t the percentage of MCs in the bone marrow smear is 5-19% and when the percentage of MCs in bone marrow smear increases more than 20%, the diagnosis changes to MCL. In the new revision of WHO classification extra cutaneous mastocytoma has been removed. Smoldering systemic Mastocytosis (SSM) in the new classification is a variant of SM while in the previous category it was a subvariant of indolent SM (ISM) [17] (Figure 3).
Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS)

CEL-NOS is a clonal eosinophilia and is considered in the presence of ≥1.5 × 10^9/L absolute eosinophil count in the peripheral blood more than 6 months. The presence of myeloblast excess (either >2% in the peripheral blood or 5–19% in the bone marrow) and cytogenetic abnormalities such as trisomy 8, t (10; 11) (p14; q21), and t (7; 12) (q11; p11). Recent studies have suggested the possibility of re-classifying some cases of “hypereosinophilic syndrome” as CEL-NOS [18].

Myeloproliferative/Myelodysplastic neoplasm (MPN/MDS)

Myelodysplastic/myeloproliferative neoplasms encompass rare clonal myeloid proliferations that show overlapping myeloproliferative and myelodysplastic characteristics, include chronic myelomonocytic leukemia, atypical chronic myeloid leukemia (BCR-ABL1 negative), juvenile myelomonocytic leukemia (JMML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable [18,19].

Chronic Myelomonocytic Leukemia (CMML)

Chronic myelomonocytic leukemia (CMML) combines pathomorphological and clinical features of myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). The presence of mutations TET2, SRSF2, ASXL1, and SETBP1 in genes often associated with CMML. This leukemia is associated with persistent peripheral blood monocytes >1×10^9/L and >10% of WBC, does not meet WHO criteria for BCR-ABL1 CML, PMF, PV, or ET,<20% blasts in the blood and bone marrow and Dysplasia in 1 or more myeloid lineages. Monocytosis is persistent (>3 months) and all non-neoplastic causes of monocytosis have been excluded. CMML is divided into two categories: a) CMML-1: blasts (including promonocytes) lower than 5% in the peripheral blood, and lower than 10% in the bone marrow and (b) CMML-2 blasts 5–19% in the peripheral blood, and 10–19% in the bone marrow or Auer rods are present. The 2016 revision of WHO classification has recommended distinction between MP-CMML (WBC count ≥13×10^9/L) and the MD-CMML (WBC <13×10^9/L). The difference in survival between the two subtypes is probably due to the higher prevalence of leukocytosis/monocytosis and of ASXL1 mutations in MP-CMML. However, this sub classification might not provide additional prognostic value [1,20].

Juvenile Myelomonocytic Leukemia (JMML)

Juvenile myelomonocytic leukemia often happens at an early age, and other diagnoses should be considered if the patient is over the age of six. This malignancy is associated with an increase in the number of monocytes > 1×10^9, blasts less than 20% in bone marrow and peripheral blood, BCR-ABL negative, increased hemoglobin F, increased sensitivity to GM-CSF in vitro and the presence of mutations PTPN11, KRAS, NRAS, CBL or NF1 that involve RAS signaling pathway or anomalies of the monosomy 7 [21,22].The 2016 classification has been refined by the addition of hyper phosphorylation of STAT-5. Almost all JMML patients respond to GM-CSF indicating activation of STAT 5. This response is seen exclusively in JMML compared to healthy controls and other pediatric MPNs. So it is an important diagnostic tool [23].

Diagnostic Criteria for Atypical CML (aCML), BCR-ABL1-

By 2016 WHO classification aCML is a rare subdivision of MDS/MPN. It is now better defined in terms of molecularity and can be separated from the CNL cases, which are usually characterized by neutrophilia and which are part of the MPN family. However, the CNL is related to the presence of the CSF3R mutation, and this finding in aCML is very rare (<10%). While the aCML is related to the SETBP1 or ETNK1 mutation (in more than a third of aCML cases) and the mutations that are seen in MPN, (such as JAK2; CALR; MPL) are not in the aCML [1].

AML with Recurrent Cytogenetic Abnormalities

The cytogenetic changes in blood malignancy were a considerable revolution in diagnosis and treatment of the mentioned disease because it indicated a new way for researchers and physician of this field. There was not much change in the classification of leukemia based on cytogenesis between 2008 and 2016.

AML with t (8; 21) (q22; q22), RUNX1RUNX1T1:

The t(8; 21) results in fusion of RUNX1 gene located on chromosome 21 and RUNX1T1 gene on chromosome 8 that encodes the CBFA2T1 protein. The criteria for this AML is unusual, and differ from other AML, in biological characteristics [24]. According to WHO criteria blast
count is 20% or more in bone marrow or blood, except in the patients that have AML with t(15;17), t(8;21), inv(16) or t(16;16). Myeloblasts, Promelocyte, monoblasts, promonocyte, and megakaryoblasts are considered to be favorable risk for complete recovery and survival [26]. These patients express the T lymphoid marker CD19 and less CD7. They may also express the CD56 marker [25]. The determination of minimal residual disease (MRD) in AML patients with t (8; 21) may be done with specific chromosomal rearrangement, multiparametric flow cytometry (FC) and real time RT-PCR (RQ-PCR) [27]. This translocation has not changed in accordance with Table 4 in the 2008 and 2016 WHO classifications.

### Table 4: Comparison AML classification in 2008 and 2016.

<table>
<thead>
<tr>
<th>2008</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML with t(8;21)(q22;q22);RUNX1RUNX1T1</td>
<td>AML with t(8;21)(q22;q22);RUNX1RUNX1T1</td>
</tr>
<tr>
<td>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11</td>
<td>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11</td>
</tr>
<tr>
<td>AML with t(15;17)(q22;q12); PML-RARA</td>
<td>APL With PML-RARA</td>
</tr>
<tr>
<td>AML with t(9;11)(p22;q23); MLLT3-MLL</td>
<td>AML with t(9;11)(p22;q23); MLLT3-KMT2A</td>
</tr>
<tr>
<td>AML with t(6;9)(p23q34); DEK-NUP214</td>
<td>AML with t(6;9)(p23q34); DEK-NUP214</td>
</tr>
<tr>
<td>AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1</td>
<td>AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);GATA2;MECOM</td>
</tr>
<tr>
<td>AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1</td>
<td>AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1</td>
</tr>
<tr>
<td>Provisional entity: AML with mutated NPM1</td>
<td>AML with mutated NPM1</td>
</tr>
<tr>
<td>Provisional entity: AML with mutated CEBPA</td>
<td>AML with biallelic mutated of CEBPA</td>
</tr>
<tr>
<td>Therapy-related myeloid neoplasms</td>
<td>Therapy-related myeloid neoplasms</td>
</tr>
<tr>
<td>Myelodysplasia related change</td>
<td>Myelodysplasia related change</td>
</tr>
</tbody>
</table>

**AML with inv (16) (p13.1q22) or t (16; 16) (p13.1; q22); CBFB-MYH11**

At the molecular level, inv (16) leads to the fusion of the core-binding factor B (CBFB, PEBP2B) gene on chromosomal band 16q22 with the smooth muscle myosin heavy chain (MYH11) gene on 16p13. On cytogenetic analysis inv (16) has been seen in 8% of adult AML patients [28]. Patients with inv (16) have an approximately favorable outcome, especially when treated with high-dose cytarabine-based consolidation regimens [29]. It is usually associated with acute myelomonocytic leukemia with eosinophilia (AML M4-Eo by the French American British classification) [30]. This translocation also has not changed in accordance with Table 4 in the 2008 and 2016 WHO classifications.

**AML with PML-RARA**

The PML/RARA oncoprotein induces acute promyelocytic leukemia (APL) through homo- and heterodimerization with RXRA [31]. The PML gene encodes the tumor suppressor protein PML, and at (15; 17) translocation results in a PML-RARA fusion protein which is found in most cases of APL [32] (more than 98%) and a limited number of patients without phenotypes of t (15; 17) which have different types of X-RARA-fusion [33]. Acute promyelocytic leukemia (APL) is pathologically characterized by the accumulation of promyelocytic blast cells in the bone marrow and blood [34]. This abnormality was previously known as APL with t (15; 17) (q24.1; q21.2) (previously called AML-M3). But according to Table 4, the classification for 2016 has changed the new updated names in order to emphasize the significance of the PML-RARA fusion; which may result from complex cytogenetic rearrangement other than t(15;17) (q24.1; q21.12). APL with this fusion is renamed APL with PML-RARA [1]. The RQ-PCR is used to identify this fusion [35]. All-trans retinoic acid (ATRA), one of two medicines, is given to treat the disease that communicates with the ligand binding domain present on the RARA moiety of the chimeric oncoprotein and causes both its transcriptional activation; as a result, its protolithic property disappears and leads to the differentiation of granulocytes in PML cells. Arsenic trioxide (ATO) also has an effective effect on treatment of PML. The simultaneous use of both medicines will increase their ability to cure APL. Thus, the ability of ATRA and ATO to eliminate PML/RARA a critical parameter for the success of the APL treatments is considered [36,37]. But some patients with X-RARA-
fusion are resistant to ATRA and AS203 treatment [33]. For example, in t (11; 17) zinc finger protein PLZF and RARA infuse together and the morphology of the blasts and response to retinoic acid are different with t (15; 17) [38]. Therefore, in order to implement an appropriate therapeutic method in leukemia patients with AML-M3 morphology if they are negative for t (15:17), other related mutations with gene fusion RARA are considered.

**AML with t (9; 11) (p22; q23); MLLT3-KMT2A**

As indicated in Table 4, due to the new revision of WHO classification the name of MLL has changed to KMT2A which was previously known as ALL-1, MLL1[1] At the molecular level, this transplantation includes the KMT2A gene in 11q23 and the MLLT3 (mixed-lineage leukemia translocate to 3) gene in 9p21, resulting in the KMT2A-MLLT3 fusion gene product. The prognosis of this translocation is controversial. According to some reports this anomaly has a good prognosis, while some do not confirm this [39].

**AML with t (6; 9) (p23; q34); DEK-NUP214**

Acute myelogenous leukemia (AML) with translocation involving breaks at band 23 of the short arm of chromosome 6 and band 34 of the long arm of chromosome 9, t (6; 9) (p23; q34) [40]. In 1% of cases AML [41]. Patients with this translocation give a poor response to chemotherapy, and the rate of relapse after healing is high [42]. This translocation was recognized in 1976. Usually the t(6;9) presents as de novo AML, morphologically associated with FAB type M2, bone marrow (BM) basophilia, Auer rods, and dysplasia [43]. Immunophenotype analysis is usually positive for CD13, CD33, CD34, CD38, CD45, HLA-DR, and TdT [44]. This translocation also has not changed according to Table 4 in the 2008 and 2016 WHO classifications.

**AML with inv (3) (q21.3q26.2) or t (3; 3) (q21.3; q26.2); GATA2; MECOM**

The subtypes acute myeloid leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); EVI1 protein are involved in regulation of transcription factors critical for hematopoiesis (eg, GATA 1, GATA2) and in epigenetic regulation [45] RPN1-EVI1 in the WHO 2008 classification is now renamed as inv(3) (q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2;MECOM in the WHO 2016 classification according to Table 4. Because the inv (3) (q21.3q26.2) or t (3; 3) (q21.3; q26.2) was not found to represent a fusion gene, but for changing position a distal GATA2 enhancer results in the overexpression of MECOM (EVI1) and functional acute failure of GATA2 [46]. Deregulated EVI1 expression is associated with low Complete Ratio rate and inferior survival; this effect is most pronounced in cytogenetic intermediate-risk AML. Allogeneic HSCT may improve survival of AML with high EVI1 [45]. Overexpression of EVI1 is caused by the inappropriate transcriptional control of the ectopic GATA2 regulatory element while GATA2 transcriptional impairment results from the removal of that same enhancer from its genomic origin. Thus it has been accepted that not RPN1, but rather the GATA2 locus is the source of the ectopic enhancer activating EVI1 in leukemia concealed inv (3)/t (3). This abnormality is seen in de novo AML and in therapy-related MDS/AML [47].

**AML (megakaryoblastic) with t (1; 22) (p13; q13); RBM15-MKL1**

The mutual translocation t (1; 22) (p13; q13) involving the RBM15 and MKL1 genes is an unusual abnormality that occurs under the action sets with a mutagenesis of the megakaryocytic category (AML-megakaryoblastic or AMKL) [48] which is characterized by abnormal megakaryoblasts that express platelet-specific surface glycoprotein. Bone marrow biopsy shows intense myelofibrosis, which is often difficult to aspiration of these patients [49]. This abnormality includes less than 1% of acute myeloid leukemia, but it has a higher prevalence in children. Patients with this abnormality frequently present anemia, thrombocytopenia, and organomegaly, especially hepatosplenomegaly [50] which are immunophenotypically positive for CD41, CD42b, and CD61 [51]. The prognosis of AMKL is usually bad when compared to other AML types, but AMKL with t (1; 22) (p13; q13) appears to have a better prognosis than AMKL without this cytogenetic change [50]. This translocation also has not changed in accordance with Table 4 in the 2008 and 2016 WHO classifications.

**AML with mutated NPM1 [nucleophosmin (nucleolar phosphoprotein B23, numatrin)]**

The most common NPM1 mutation is a 4–base pair duplication, 956dupTCTG in exon 12 (called type A), that causes a shift in the reading frame leading to replacement of the last 7 amino acids by 11 different ones in the C-terminal portion of nucleophosmin [52]. Pleiotropic functions mutations lead to abnormal cytoplasmic localization of the protein that can be diagnosed by immunohistochemistry on bone marrow sections.
mutations found in 25%-35% of AML [46]. Mutations of NPM1, in t(2;5)(p23;q35) in anaplastic large-cell lymphoma, t(3;5)(q25;q35) in AML, and t(5;17)(q35;q21) in acute promyelocytic leukemia are reported [52]. Leukemic blasts show high CD33 and absent to low CD34 expression associated with myelomonocytic or monocytic morphology with higher WBC and platelet counts and increased bone marrow blast percentages, higher prevalence in female sex. In younger adults with mutated NPM1 without FLT3-ITD, standard induction therapy followed by repetitive cycles of HiDAC is a reasonable treatment option; patients may not benefit from allogeneic HSCT in first complete remission. Favorable impact of NPM1 mutations in older patients is observed. Older patients with NPM1-mutated AML may benefit from intensive conventional chemotherapy. NPM1 mutations are associated with up regulation of miR-10a, miR-10b, and miR-196a, all of which reside in the genomic cluster of HOX genes that is found to be consistently overexpressed in this molecular subset [46]. Furthermore AML with mutated NPM1 shows a favorable prognosis in the absence of fms-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation. For this reason, as indicated in Table 4, for AML with mutated NPM1 the 2008 WHO classification has been classified as a new category and has not changed in the 2016 version of WHO [53].

**AML with Biallelic Mutations of CEBPA**

The CEBP gene is located on chromosome band 19q13.1. The intron is low and rich in GC (approximately 75% containing GC) and encodes a protein that belongs to basic leucine zipper family of transcription factor. It is expressed in the cells of the myelomonocytic cell and specifically up regulated during granulocyte differentiation [54]. The finding that the improved prognosis associated with AML with mutated CEBPA, which is seen in 5% to 14% of AML, is associated with biallelic, but not single, mutations of the gene which resulted in a change in that disease definition to require biallelic mutations (Table 4). Most AMLs with CEBPA mutations simultaneously carry 2 mutations (CEBPA double-mutation), usually biallelic (Nonsense mutations affecting the N-terminal region result in a truncated CEBPA isoform with dominant-negative properties, and in-frame mutations in the C-terminal basic region leucine zipper domain result in CEBPA proteins with decreased DNA binding or dimerization activity [46], whereas single heterozygous mutations (CEBPA single mutation) are less frequently seen. CEBPA double-mutation is associated with a unique gene expression profile [1]. Double mutant/biallelic cases (CEBPA dm) predict a favorable prognosis– low frequency of other mutations or other cytogenetic abnormalities that impair hematopoetic differentiation. CEBPA mutations are predominantly found in CN-AML and in cases with 9q deletion [46]. Presence of NPM1 and biallelic CEBPA trump morphological evidence of multilineage dysplasia when a mutation of NPM1 or biallelic mutation of CEBPA is present [47]. CEBPA mutations have been associated with an up regulation of members of the miR-181 family in CN-AML. Therapeutic recommendations are standard induction chemotherapy followed by three to four cycles of high-dose cytarabine. Also, AML with double CEBPA mutations may not benefit from allogeneic HSCT. In younger adults, standard induction therapy followed by repetitive cycles of HiDAC is a reasonable treatment option for AML with CEBPA mutation [46].

**AML with BCR-ABL**

As indicated in Table 4 AML with BCR-ABL1 is added to the new category of the 2016 WHO classification. This is rare in de novo AML cases, approximately 0.5-3 % [55]. Although the diagnostic distinction between de novo AML with BCR-ABL1 and blast transformation of CML may be difficult without adequate clinical information, in recurrent not universal deletion of antigen receptor genes (IGH, TCR), IKZF1 and/or CDNK1A gene may support a diagnosis of de novo disease versus by Blasting Phase of CML[1]. This criteria, suggested for differentiating Philadelphia chromosome (Ph+) AML from CML-MBC (CML in myeloid blastic crisis) includes an absence of a clinical history of a hematologic malignancy, lack of evidence of chronic phase or accelerated phase of CML and lack of clinical and laboratory features of CML such as splenomegaly and basophilia [56]. In CML-MBC, the most common additional abnormalities are trisomy 8, trisomy 19 or is chromosome 17q, in addition to t(9;22) [55]. These findings support the identification of AML with BCR-ABL1 as a distinct entity from CML myeloid blast crisis. A combination of AML chemotherapy and continuing Imatinib, can provide recovery and a further allogeneic stem cell transplant (ASCT) is the best stabilizing therapy for the patient with Ph+ AML [57].

**AML with Mutated RUNX1**

As seen in Table 4, a provisional category of AML with mutated RUNX1 (runt-related transcription factor 1) is a myeloid transcription factor described as recurrently mutated in de novo acute myeloid leukemia (AML; ~ 10%) [58]. The RUNX1 gene is located at chromosomal band 21q22. It contains a “Runt homology domain” (RHD) that is responsible for heterodimerization with the core-
binding factor (or PEBP2) as well as transcription factor and for DNA binding. The second important part of the RUNX1 protein is the transactivation domain followed by a 5-amino acid sequence of the gene products [59]. This gene is required for definitive hematopoiesis, and its functional mutation leads to leukemia [60]. Multivariate Cox regression analysis defends RUNX1 as a new entity in the AML without taking the dysplasia characteristics into consideration [58]. RUNX1 mutations have been associated with undifferentiated (M0) morphology and with specific chromosome aberrations, such as trisomy 21 and trisomy 13 [46]. This new provisional disease category appears to represent a biologically distinct group with a possibly worse prognosis than other AML types [1].

AML with Mutated C-KIT

C-KIT and its ligand (stem cell factor) play a key role in the survival, proliferation, differentiation and activation of hematopoietic progenitors. Proto-oncogene C-KIT is expressed in 80% of cases of AML, which represents a poor prognosis. Identifying the c-kit makes treatment more specific and appropriate [61,62].

AML with Mutated Nup

The NPC is one of the largest and most complex proteins in the cell, composed of about 30 proteins in multiple copies. The task is to set up a nuclear-cytoplasmic transport of macromolecules larger than 40 KD. NPC consists of nucleoproteins. Many AML, N-terminal Nup98 proteins have been displaced with the C-terminal of 30 different partners. But how this mechanism works is not well known [63,64].

AML with Myelodysplasia Related Change

AML with multilineage dysplasia is now renamed “AML with myelodysplasia-related changes.” Multilineage dysplasia (MLD), refers to cases with dysplastic features in 2 hematopoietic lineages. Based on WHO cases with blasts more than 20% in the bone marrow or peripheral blood that do not meet the criteria for classification “AML with recurrent genetic abnormalities” or “therapy related AML (t-AML)” [65] and myelodysplasia-related changes (MRC-AML), present myelodysplasia-related phenotype and cytogenetic abnormalities and/or exhibit dysplasia in 50% or more of the cells in two or more myeloid lineages and/or history of myelodysplastic syndrome (MDS). However, the clinical significance of this morphologic feature has been questioned. Myelodysplasia-related changes (MRC-AML) is considered to be a high-risk disease, since it is secondary, and is associated with undesirable cytogenetics, older people, and severe therapies [66].

AML with Mutated FLT3

Mutations in the fms-related tyrosine kinase 3 (FLT3) gene are found in many AML subtypes. In up to 30% of acute myeloid leukemia (AML) patients [67]. In general, FLT3 mutations can be divided into 2 categories: 1- internal tandem duplications (FLT3/ITD mutations) in or near the juxtamembrane domain of the receptor and 2-point mutations resulting in single amino acid exchange occurring within the activation loop of the tyrosine kinase domain (FLT3/TKD mutations) [65]. Internal tandem duplication mutations of the FMS-like tyrosine kinase-3 receptor (FLT3/ITD mutations) are one of the most common molecular abnormalities found in de novo acute myeloid leukemia (AML) [68]. Approximately 20–30% of AML patients carry an internal tandem duplication (ITD) mutation in the FLT3 gene but mutations in the tyrosine kinase domain (TKD) of FLT3 are less frequent (7%) and currently have no clinically significant impact [69]. FLT3 appertain to the class III receptor tyrosine kinase (RTK) family, including FMS, c-KIT, platelet derived growth factor receptor, and platelet-derived growth factor receptor β [70]. FLT3 plays an important role in hematopoiesis by regulating proliferation, differentiation, and apoptosis of cell progenitors [71]. The prognosis for patients with FLT3-ITD mutations in the juxtamembrane domain, is worse than the patients with wild-type FLT3 when treated with standard therapy [72]. Allogeneic HSCT should be considered in AML with FLT3-ITD. FLT3-ITD has been reported to be associated with miR-155 up regulation [46].

AML with Therapy Related Myeloid Neoplasm

Therapy related myeloid neoplasm, depending on the number of blast, can be divided into two groups of t-AML and t-MDS, but it is preferable to look at them as a single biologic disease group. Therapy related myeloid neoplasm is a consequence of chemotherapy for solid tumors, which can be classified into two categories: 1. An alkylation agent / radiotherapy-related type; and 2. A topoisomerase II inhibitor-related type.

But this division is not effective in treatment [73]. What is useful in therapy and prognosis is genetic abnormalities. A new issue included in the 2016 classification is the answer to why chemotherapy in some people leads to cancer instead of curing them. Germ line
mutation in cancer susceptibility genes increases cancer after chemotherapy. By revealing the history of the family, the cancer can be detected so they need more follow up [1] (Table 5).

<table>
<thead>
<tr>
<th>AML FAB classification</th>
<th>2008</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0 (AML with minimal differentiation)</td>
<td>AML with minimal differentiation</td>
<td>AML with minimal differentiation</td>
</tr>
<tr>
<td>M1 (AML without maturation)</td>
<td>AML without maturation</td>
<td>AML without maturation</td>
</tr>
<tr>
<td>M2 (AML with maturation)</td>
<td>AML with maturation</td>
<td>AML with maturation</td>
</tr>
<tr>
<td>M3 (acute promyelocytic leukemia)</td>
<td>Acute myelomonocytic leukemia</td>
<td>Acute myelomonocytic leukemia</td>
</tr>
<tr>
<td>M4 (Acute myelomonocytic leukemia)</td>
<td>Acute monoblastic/monocytic leukemia</td>
<td>Acute monoblastic/monocytic leukemia</td>
</tr>
<tr>
<td>M5 (Acute monoblastic/monocytic leukemia)</td>
<td>Acute erythroid leukemia</td>
<td></td>
</tr>
<tr>
<td>M6 (Acute erythroid leukemia)</td>
<td>Pure erythroid leukemia</td>
<td>Pure erythroid leukemia</td>
</tr>
<tr>
<td>M7 (Acute megakaryoblastic leukemia)</td>
<td>Acute megakaryoblastic leukemia</td>
<td>Acute megakaryoblastic leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Table 5:</strong> Comparison of Acute Myeloid Leukemia not otherwise specified, in FAB, 2008 and 2016.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Acute Myeloid Leukemia, Not Otherwise Specified (NOS)**

As seen in Table 5, [74] in 2016 WHO classification AML with not otherwise specified, (NOS) has only a single change: The subgroup of acute erythroid leukemia and the type of erythroid/myeloid (formerly as cases of ≥50% erythroid precursors in bone marrow and ≥20% of myeloblasts in non-erythroid cells) has been excluded from the classification of the AML. In the new classification, myeloblast is always measured as a percentage of the total cells in the bone marrow. And in most cases, with <20% of the total blast cells, is now classified as MDS (usually MDS with excess blast). These changes are based on the biological relationships of the erythroid/myeloid type of acute erythroid leukemia to MDS in terms of clinical findings, morphological features, genetic abnormalities, and attempts to align the expression of blast percentages in all myeloid neoplasms [1,47]. Items with ≥50% erythroid cells and ≥20% of myeloblasts (previously known as M6 in the FAB (French-American-British) category) should now be diagnosed if they have criteria for AML with myelodysplasia-related changes. Therefore, in the new classification of WHO, dysplasia alone can be sufficient for the classification of AML with myelodysplasia-related changes. And items with ≥20% of the myeloblast that do not have AML with myelodysplasia-related changes classification criteria should be included in AML; NOS [65].

**AML Associate with Down Syndrome**

The risk of AML in patients with Down syndrome is increased. Myeloid proliferations related to Down syndrome include transient abnormal myelopoiesis (TAM) and myeloid leukemia associated with Down syndrome About [75,76]. 20% to 30% of children with myeloid leukemia had a previous history of TAM [77]. The myeloid leukemia and TAM blasts cannot be differentiated in terms of phenotypic and morphologically. In this group of malignancies blasts showed megakaryocytic differentiation with aberrant CD7 expression [78]. The mutation in GATA-1 is seen [79]. The mutation in JAK-STAT signaling pathway has been added in the 2016 classification. Because this mutation is seen only in myeloid leukemia associated with Down syndrome, while a mutation in GATA-1 is seen in TAM and myeloid leukemia. There is also a small number of leukemia cells that are unrelated to Down-syndrome that have GATA-1 mutation. Therefore, JAK-STAT reduces the probability of error in the diagnosis [77].

**AML associate with Sarcoma**

Myeloid sarcoma is a tumor lesion of immature cells of the granulocytic series that can be created anywhere in the body. Most of the tumors can be seen in soft tissues, bones, lymph nodes, peritoneum, gastrointestinal tract, etc. [80]. This tumor lesion can occur either in the form of denevo or at the same time as AML, MDS and MPD. It can be a relapse symptom of the disease. Isolated into a sarcoma in which the bone marrow is not involved. Usually sarcoma of bone marrow involvement is associated with leukemia [79]. In the 2016 classification, it is proposed to classify cases that are not associated with bone marrow involvement in a separate subgroup, since treatment for those with bone marrow involvement is different and more difficult [81].
AML Associate with Ambiguous Lineage

Leukemia with ambiguous lineage that does not express specific marker of the lymphoid either myeloid lineage, or the specific marker of both classes is expressed on blast cells [82]. In 2016, it is better to classify this category of leukemia based on genetic variation. Because it makes it more specific and more suitable for treatment [83].

Natural Killer (NK) Cell Lymphoblastic Leukemia/Lymphoma

This leukemia expresses markers CD16, CD56 and is negative for CD3. If CD123 is positive, it has dendritic origin [84]. This leukemia in the 2008 classification, according to the Table 6 was a subset of the ambiguous leukemia. Because of this, there are few specific markers that are hard to distinguish from acute myeloid leukemia. CD56 is a sensitive marker for NK detection, but not specific. Diagnosis of this malignancy is possible at a time when other leukemia is excelled [83]. In the 2016 classification, it is located in the LGL lymphoid subgroup [85] (Table 6).

### Table 6: AML associated with Ambiguous lineage.

<table>
<thead>
<tr>
<th>2008</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute undifferentiated leukemia</td>
<td>Acute undifferentiated leukemia</td>
</tr>
<tr>
<td>Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1</td>
<td>Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1</td>
</tr>
<tr>
<td>Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged</td>
<td>Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged</td>
</tr>
<tr>
<td>Mixed phenotype acute leukemia, B-myeloid, NOS</td>
<td>Mixed phenotype acute leukemia, B-myeloid, NOS</td>
</tr>
<tr>
<td>Mixed phenotype acute leukemia, T-myeloid, NOS</td>
<td>Mixed phenotype acute leukemia, T-myeloid, NOS</td>
</tr>
<tr>
<td>Natural killer (NK) cell lymphoblastic leukemia/lymphoma</td>
<td>(Provisional entity)</td>
</tr>
</tbody>
</table>

Conclusion

Adding molecular findings in leukemia has not only been able to solve the problems in diagnosis, but also has a therapeutic approach. The classification of leukemia by the WHO and the collaboration of researchers seems to promote the unknown aspects of mutations and molecular damages in this part of science, and it is still necessary to continue to reveal unknown diseases.

References


71. Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, et al. (2010) Phase IIb trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk
myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28(28): 4339.


